Biopharmaceuticals

Whitefish, Mont. – September 25, 2026 -- STEMREGEN, a maker of science-backed stem cell supplements, has landed at No. 332 on the 2026 Inc. 5000 list after posting 1,017% revenue growth over three years, far outpacing the list's 130% median.

Company secures third straight Inc. 5000 ranking as growth trajectory accelerates

STEMREGEN previously ranked No. 265 in 2025 and No. 1,765 in 2024, marking three consecutive years on the annual list of America's fastest-growing private companies. The 2026 ranking measures revenue growth from 2022 through 2025.

Seoul – September 26, 2026 -- MAYPHARM has announced the upcoming launch of HYALMASS AQUATOX, a new aesthetic formulation combining five high-interest active ingredients into a single product for the global cosmeceutical market.

MAYPHARM combines five actives into one formulation to meet multifunctional demand

The new product integrates PDRN, Exosomes, Botulinum Peptide, GHK-Cu, and Succinic Acid in one advanced skin solution. Botulinum Peptide is designed to support a smoother skin appearance, while GHK-Cu is studied for skin conditioning and regeneration. Succinic Acid is positioned for antioxidant activity, PDRN for skin regeneration and recovery, and Exosomes for advanced rejuvenation approaches.

Pune, India – September 25, 2026 -- The global AI in Clinical Trials Market is set to more than triple from USD 2 billion in 2025 to USD 7.32 billion by 2034, expanding at a 15.5% compound annual growth rate, according to Maximize Market Research.

Pharmaceutical firms accelerate AI adoption to cut trial delays

Pharmaceutical and biotechnology companies, along with contract research organizations, hospitals and research institutes, are deploying machine learning, natural language processing and deep learning to speed patient screening, cohort selection, trial design and large-scale data analysis. These tools are applied across Phase I, Phase II and Phase III trials for patient recruitment, safety monitoring, drug discovery and personalized medicine.

Pune – September 25, 2026 -- The global clinical trials market reached USD 58.19 billion in 2025 and is forecast to grow at a 6.13% compound annual rate through 2034, reaching USD 99.4 billion, according to Maximize Market Research.

North America retains dominant share on trial infrastructure and R&D spend

North America leads global trial activity, underpinned by extensive pharmaceutical and biotechnology infrastructure, significant cancer research burden, and the presence of major contract research organizations. The United States drives the bulk of regional Phase I-IV trial volume, while Canada contributes through government investment in trial infrastructure. Europe holds a substantial share as well, with the UK, France, Germany, Italy, Spain, Sweden and Austria supporting research across oncology, cardiovascular disease, CNS conditions, diabetes, obesity and autoimmune disorders.

Cambridge, Mass. – September 25, 2026 -- NeuroSense Therapeutics (NASDAQ: NRSN) cut operating expenses to $3.4 million in the first half of 2026, down from $4.7 million a year earlier, as the biotech pushes its ALS candidate PrimeC toward a Canadian regulatory filing targeted for December 2026.

NeuroSense trims R&D and G&A spending by double digits in H1 2026

Research and development expenses fell 16% to $2,102 thousand from $2,503 thousand, driven by lower subcontractor and consultant costs, partly offset by higher share-based payment expense. General and administrative expenses dropped 38.6% to $1,345 thousand from $2,189 thousand on reduced professional services spending.

Shanghai – September 25, 2026 -- IASO Biotechnology reported an 88.9% objective response rate for its dual-targeted CAR-T therapy RD140 in a first-in-human Phase 1 trial of nine heavily pretreated multiple myeloma and plasma cell leukemia patients, with the response rate reaching 100% in the higher-dose cohort.

RD140 achieves 88.9% MRD negativity in high-risk relapsed patients

The investigator-initiated trial (NCT06655519), led by Professor Jin Lu of Peking University People's Hospital, enrolled patients who had failed at least three prior lines of therapy, including two who had previously received BCMA-targeted treatment. All nine patients were triple-class exposed, and six were penta-exposed. As of the May 6, 2026 data cutoff, with a median follow-up of 6.05 months, 88.9% of patients achieved MRD negativity at the 10−5 threshold, with six reaching this benchmark as early as day 28. Median progression-free survival has not been reached.

Shanghai – September 25, 2026 -- A retrospective analysis of 102 multiple myeloma patients treated with IASO Bio's FUCASO CAR-T therapy found that patients maintaining sustained minimal residual disease (MRD) negativity showed a median CAR-T cell persistence of 463 days, compared with 272 days in patients who experienced MRD conversion — a gap of roughly 191 days. The data, drawn from the pivotal FUMANBA-1 registration study, were presented as a poster (Abstract No. PA-469) at the 2026 International Myeloma Society Annual Meeting.

San Mateo, Calif. – September 25, 2026 -- Kali Therapeutics has been named one of the 11 most promising private biotechnology companies in the 2026 Endpoints 11, a list curated annually by Endpoints News editors from hundreds of private candidates.

Kali advanced two clinical candidates and closed a Sanofi licensing deal in just over two years

Founded in July 2024, the clinical-stage biotech moved from formation to two molecules in the clinic and a worldwide partnership with Sanofi inside roughly two years. The honorees were announced Thursday, September 24, 2026, at an awards gala at The State Room in Boston.

Emeryville, Calif. – September 25, 2026 -- Slingshot Biosciences has appointed Dr. Nimisha Srivastava as Chief Executive Officer, effective September 23, 2026, elevating the company's former Chief Operating Officer to its top leadership post.

Srivastava succeeds Glenn Bilawsky as CEO of the flow cytometry controls maker

Glenn Bilawsky is transitioning out of the CEO role at Slingshot Biosciences, a company specializing in precision-engineered cell mimics used as reference materials in flow cytometry. The Board of Directors credited Bilawsky's leadership contributions during his tenure.

Jeollanam-do – September 25, 2026 -- Researchers at Chonnam National University have demonstrated that dichloromethane, a widely used industrial solvent, can directly drive amide bond formation between carboxylic acids and amines, offering manufacturers a cheaper and less hazardous alternative to conventional coupling reagents. The findings, led by Professor Sunwoo Lee of the Department of Chemistry, were published online on July 6, 2026, and appeared in Volume 148, Issue 27 of the Journal of the American Chemical Society on July 15, 2026.